Results reported October 13, 2026 (before market open) | NYSE: UNH | Managed Healthcare
The Quick Take
UnitedHealth delivered a clean beat and raised its full-year outlook. Adjusted EPS of $4.69 topped the Street’s roughly $4.15 and jumped 61% from $2.92 a year ago. Revenue of $112.7B edged past expectations of about $111.5B, although it slipped slightly from $113.2B last year. The story is margin repair: the medical care ratio improved to 88.4% and earnings from operations rose to $6.6B from $4.3B. The catch is that the top line is shrinking as the company sheds unprofitable business.
Results
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Revenue | $112.7B | -0.4% YoY; consensus about $111.5B |
| Adjusted EPS | $4.69 | vs $2.92 a year ago; consensus about $4.15 |
| GAAP EPS | $4.56 | vs $2.59 a year ago |
| Earnings from operations | $6.6B | vs $4.3B a year ago |
| Medical care ratio | 88.4% | vs 89.9%; includes $610M favorable prior-period reserve development |
| Operating cost ratio | 12.8% | vs 13.5% |
| Cash flow from operations | $5.1B | 1.2x net income |
What Drove the Quarter
- UnitedHealthcare: Revenue was $86.3B (vs $87.1B). Operating earnings rose to $2.8B from $1.8B, and operating margin widened to 3.3% from 2.1%. Members served fell to 48.3M on employer attrition, Medicaid eligibility changes and Medicare Advantage declines.
- Optum: Revenue was $66.9B (vs $69.2B), but operating earnings climbed to $3.7B from $2.5B, a 5.6% margin vs 3.6%.
- Optum Health: Revenue fell 10% to $22.9B as the company exited markets without enough value-based care presence. Operating earnings rose to $735M from $41M.
- Optum Insight: Revenue rose 3% to $5.5B; operating earnings increased to $1.3B from $920M.
- Optum Rx: Revenue was flat at $39.9B and operating earnings rose to $1.7B from $1.5B, though adjusted scripts fell to 393M from 414M.
Guidance
| Metric | Outlook |
|---|---|
| 2026 adjusted EPS | At least $20.50 (raised) |
| 2026 GAAP EPS | At least $19.50 (raised) |
| Debt-to-capital | 41.7% now; target about 40% by year-end |
Year-to-date, the company has repurchased $5.0B of stock and paid $6.2B in dividends.
What Management Said
CEO Stephen Hemsley said the results “reflect the discipline and execution our teams are bringing to every part of our business.”
Why the Numbers Matter
Roughly $610M of the medical cost improvement came from favorable reserve development from prior periods, so not all of the margin gain is repeatable. Even stripping that out, the underlying cost ratio and operating cost ratio both improved, and cash conversion was healthy. The market is rewarding a turnaround that is now visible in the numbers, while still asking when revenue stops shrinking.
Risks
- Membership is falling across commercial, Medicaid and Medicare Advantage, which pressures future revenue.
- Reserve releases flatter the quarter and may not recur.
- Optum Rx script volume dropped about 5% year over year.
- Debt-to-capital rose slightly from 41.2% in Q2 and must still come down to hit the year-end target.
- Policy and regulatory changes in Medicare Advantage and Medicaid remain a standing threat.
Recommendation: BUY (accumulate on weakness)
Earnings power is recovering faster than the market expected: EPS up 61%, guidance raised, and margins widening in every major unit. The shrinking top line is a deliberate trade of volume for profitability, and it is working. Investors who can tolerate regulatory headline risk can build a position gradually. Those who want more proof may wait for another quarter with a lower reliance on reserve releases.
This is educational analysis, not personalized investment advice. Do your own research before investing.
Sources: UnitedHealth Group Q3 2026 earnings release (SEC Form 8-K); 24/7 Wall St. earnings calendar for consensus estimates. Consensus figures vary slightly by provider.
#TradingTips #TradingSetup #trending #TradingDiscipline #stocktrading #StockInFocus #StockToWatch #US #USMarket #brent #GlobalMarketUpdates #DowJones #Nasdaq #NYSE #UnitedHealth
Leave a Reply